MyFinsight
Home
Blog
About
Contact
Download
Download image
Exercise of share options
$12,371K
Net cash provided by
financing activities
$12,371K
(decrease) increase in net
cash and cash...
-$14,681K
Canceled cashflow
$12,371K
Proceeds from sale of
marketable securities
$18,000K
Share-based compensation
expense
$37,698K
Increase in accrued
expenses
$15,889K
Deferred income taxes
$14,790K
Depreciation
$3,266K
Non-cash lease expense
$2,348K
Other
-$2,113K
Net cash used in
investing activities
-$16,340K
Canceled cashflow
$18,000K
Net cash (used in)
provided by operating...
-$10,712K
Canceled cashflow
$76,104K
Total revenue
$400,016K
Purchase of marketable
securities
$30,000K
Purchase of property,
plant and equipment
$4,340K
Net loss
-$35,514K
Canceled cashflow
$400,016K
Unrealized gains on
marketable securities
$19,728K
Increase in accounts
receivable
$7,336K
(increase) decrease in
prepayments and other...
$6,740K
Unrealized foreign
exchange losses (gains)
$6,385K
Increase in other
operating assets
$6,177K
(decrease) increase in
accounts payable
-$2,456K
Decrease in operating
lease liabilities
-$2,093K
Decrease in deferred
revenue
-$387K
R&d
expenses-External RD
$189,584K
Sg&a-Other Selling General
And Administrative...
$87,836K
Other segment
expense, net
$54,468K
R&d
expenses-Salaries And Other...
$49,898K
Sg&a-Salaries And Other
Employee Related Cost
$48,657K
Cost of revenue from
sale of therapies
$5,087K
PRAMEPrograms
$82,594K
Other Clinical And Pre
Clinical Costs
$59,716K
Tebentafusp Programs
$40,824K
Infectious Disease
Programs
$6,450K
Back
Back
Cash Flow
source: myfinsight.com
Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR)